Is mRNA the Future of Flu Vaccines?

Influenza is familiar, but it should not be underestimated. Seasonal flu causes illness every year and can be especially dangerous for older adults, young children, pregnant people, and those with chronic medical conditions. Unlike measles, which has a very stable vaccine target, influenza viruses change frequently. That means flu vaccines must be updated regularly, and protection can vary from season to season.

Traditional flu vaccines are valuable and have saved many lives, but they have limitations. Some are made using egg-based or cell-based production systems, and strain selection must happen months before flu season. If circulating viruses drift away from the predicted strains, vaccine effectiveness can be lower.

This is why mRNA flu vaccines are attracting attention. mRNA vaccines can be designed and manufactured more rapidly once the genetic sequence of the target strain is known. They also allow researchers to test updated antigen combinations more flexibly.

The recent Phase 3 data for Moderna’s mRNA-1010 are an important milestone. In adults aged 50 years and older, mRNA-1010 reduced RT-PCR-confirmed influenza-like illness more effectively than standard-dose licensed vaccines. The study reported 2.0% influenza-like illness in the mRNA-1010 group versus 2.8% in the comparator group, corresponding to 26.6% relative vaccine efficacy.

This does not mean all questions are answered. Older adults in the U.S. often receive high-dose or adjuvanted flu vaccines, so regulators and clinicians will want to understand how mRNA-1010 compares with those options. Safety, reactogenicity, durability, strain coverage, cost, and annual manufacturing strategy also matter.

Prevention still starts with annual flu vaccination, staying home when sick, hand hygiene, ventilation, and prompt antiviral treatment for high-risk patients when clinically appropriate.

Take-home message: mRNA flu vaccines are not just a COVID-era idea. They may become part of the next generation of seasonal influenza prevention, but careful evidence and transparent communication are essential.

Reference：https://www.nejm.org/doi/abs/10.1056/NEJMoa2516491